Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

FDA Drug Approval for 2014 Is Ahead of 2013

New York, NY, September 8, 2014 WSJ Pharmalot, a pharmaceutical industry blog of The Wall Street Journal, reports an encouraging statistic:  For the year to date, the Food and Drug Administration (FDA) has approved more drugs than it did in all of 2013.

According to Pharmalot, so far this year, the FDA has approved 27 novel new medicines, a tally that includes biologics and which matches the 27 such medicines approved for all of 2013.  At this rate, the FDA may come close to matching the 39 novel new medicines approved in 2012.

The number of such drugs approved each year by the FDA is closely watched as a sign of agency efficiency, which greatly affects the well being of patients as well as the fortunes of drug makers and their investors.

However, determining an approval rate is tricky, Pharmalot noted.  That’s because the applications that the FDA receives each year almost never equate with the actual drugs that are approved in the same year. An FDA spokeswoman explains that applications are reviewed and approved on a rolling basis.

To read the full Pharmalot story, click here.

Written by Ed Silverman, Pharmalot explores the fast-moving, complicated world that develops and markets medicines — and the drug makers that are attempting to replenish their pipelines while grappling with pricing and regulatory dictates, among many other challenges.